Objective Accurate evaluation of tumor programmed death ligand 1 (PD-L1) expression can
assist in predicting whether a patient will respond to anti-PD-L1 therapy. In this study, we …

Background Evaluation of programmed cell death ligand 1 (PD‐L1) expression can be
made on both resection specimens and diagnostic biopsies; however, more than 30% of …

Background In non-small cell lung cancer (NSCLC), analysis of programmed cell death
ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to …

Background: Immunotherapy currently stands as a novel treatment option, specifically in
cases of advanced non-small cell lung carcinoma (NSCLC). Expression of programmed …

Background Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)
pathway-targeted immunotherapy has become the standard option of care in the …

Purpose To explore the relationship between [18 F] fluorodeoxyglucose (18 F-FDG uptake)
and PD-L1 expression and determine the usefulness of 18 F-FDG PET/CT for evaluating the …

Aim: We evaluated the metabolic characteristics of small-sized lung cancer using 18F-
fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG …

The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown.
The aim of this study was to investigate the impact of neoadjuvant chemotherapy (NACT) on …

In clinical practice, programmed death ligand 1 (PD-L1) detection is prone to nonspecific
staining due to the complex cellular composition of pleural effusion smears. In this study …

Introduction Programmed death-ligand 1 (PD-L1) copy number gains may be predictive of
clinical response to immunotherapy in NSCLC. This study investigated PD-L1 copy number …